1198438-39-9

Basic information

• Product Name: 6-Bromo-1-methyl-1H-indazol-4-amine
• Synonyms: 6-Bromo-1-methyl-1H-indazol-4-amine
• CAS NO: 1198438-39-9
• Molecular Formula: C₈H₈BrN₃
• Molecular Weight: 226.07322
• Mol File: 1198438-39-9.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.76
• CAS DataBase Reference: 6-Bromo-1-methyl-1H-indazol-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-1-methyl-1H-indazol-4-amine(1198438-39-9)
• EPA Substance Registry System: 6-Bromo-1-methyl-1H-indazol-4-amine(1198438-39-9)

Safety Data

• Hazardous Substances Data: 1198438-39-9(Hazardous Substances Data)

Usage

General Description

6-Bromo-1-methyl-1H-indazol-4-amine, also known as BML-210, is a chemical compound that is used in the field of medicinal chemistry and drug development. It is a potent and selective inhibitor of peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor that is involved in the regulation of glucose and lipid metabolism. BML-210 has been studied for its potential therapeutic applications in treating metabolic disorders such as type 2 diabetes and obesity. It has also shown promise in inhibiting the growth of cancer cells by targeting PPARγ signaling pathways. Due to its pharmacological properties, BML-210 continues to be researched for its potential as a therapeutic agent for various diseases and conditions.

Upstream product

• 864550-40-3 5-bromo-2-methyl-3-nitroaniline 
• 606-20-2 2,6-dinitrotoluene 
• 95192-64-6 5-bromo-2-methyl-1,3-dinitrobenzene 
• 885518-46-7 6-bromo-4-nitro-1H-indazole 
• 885518-50-3 6-bromo-1H-indazole-4-amine 
• 74-88-4 methyl iodide 

Downstream Products

• 1198803-85-8 N-{6-[5-{[(2,4-difluorophenyl)sulfonyl]amino}-6-(methyloxy)-3-pyridinyl]-1-methyl-1H-indazol-4-yl}-2-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-thiazole-4-carboxamide 
• 1310556-85-4 2-methyl-N-(1-methyl-6-{1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-indazol-4-yl)-1,3-thiazole-4-carboxamide 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Indazole compounds and application thereof to preparation of IDO inhibitors

The invention discloses indazole compounds as shown in a formula (i) or (II) which is described in the specification, and a preparation method thereof, and application of the compounds as IDO inhibitors. The compounds provided by the invention can be used for preventing and/or treating a plurality of diseases, such as Alzheimer's disease, cataract, infections related to cellular immune activation,autoimmune diseases, AIDS, cancers, depression, the metabolic disorder of tryptophan or the like.

NOVEL COMPOUNDS

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.